EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents

Hanin Harbi iD, Reimar W Thomsen iD, Carina Lundby iD, Jacob Volmer Stidsen, Kurt Højlund iD, Jesper Ryg, Mette Reilev, Anton Pottegård iD

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11086-11094

DOI: 10.1111/dom.71308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.09.2026. Verfasst von Hanin Harbi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Foundation, Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Care home admission often reflects frailty and limited life expectancy, potentially altering the benefit‐harm balance of glucose‐lowering drug (GLD) treatment for type 2 diabetes (T2D). Real‐world data on treatment patterns in this setting remain limited. We examined GLD use for T2D among Danish care home residents. Materials and Methods We conducted a nationwide, population‐based drug utilisation study of all individuals admitted to Danish care homes between 2018 and 2023, using linked national health registries.

Results

Among 88 658 residents (median age: 84 years [IQR: 78–90]; 60% women), 13% ( n = 11 101) used GLDs for T2D at admission, with 84% continuing treatment beyond 2 years. Residents using GLDs at admission had long‐standing diabetes (median duration: 12 years [IQR: 6.8–15]), relatively low glycated haemoglobin levels (median: 6.9% [IQR: 6.3–7.8]; 52 mmol/mol [45–62]) with little change around admission, and 43% used more than one GLD class, most commonly metformin (70%) and insulin (36%; basal: 30%; bolus: 16%). Use of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors increased over time but remained limited (13% and 24%, respectively, in 2023), despite a high prevalence of cardiorenal disease (84%), and did not differ by cardiorenal disease status. Overall GLD use remained stable around admission, but initiation spiked 3 months before admission (36 initiators/10 000 residents), often following hospitalisation (63%) and primarily involved bolus insulin initiated by hospital physicians.

Conclusions

GLD use for T2D among Danish care home residents is high and shows limited deintensification and potential misalignment with guideline recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsHumansFemaleDenmarkMaleAged, 80 and overNursing Home ResidentsAgedRegistriesInsulin SecretagoguesGlycated HemoglobinSodium-Glucose Transporter 2 InhibitorsMetformin

Stichwörter der Autor:innen

antidiabetic drugpharmaco‐epidemiologyreal‐world evidencetype 2 diabetes

Substanzen

Hypoglycemic AgentsInsulin SecretagoguesGlycated HemoglobinSodium-Glucose Transporter 2 InhibitorsMetformin

Autor:innen und Institutionen

  • Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Hospital Pharmacy Funen, Odense University Hospital, Odense, Denmark.
  • Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.
  • Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Hanin Harbi, Reimar W Thomsen, Carina Lundby, Kurt Højlund, Anton Pottegård

Förderung

  • Novo Nordisk Foundation
  • Novo Nordisk Fonden

Zitieren

APA

Harbi, H., Thomsen, R. W., Lundby, C., Stidsen, J. V., Højlund, K., Ryg, J., Reilev, M., & Pottegård, A. (2026). Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents. Diabetes, Obesity and Metabolism, 28(12), 11086-11094. https://doi.org/10.1111/dom.71308

Vancouver

Harbi H, Thomsen RW, Lundby C, Stidsen JV, Højlund K, Ryg J, et al. Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents. Diabetes, Obesity and Metabolism. 2026;28(12):11086-11094. doi:10.1111/dom.71308

BibTeX
@article{Harbi2026,
  author = {Harbi, Hanin and Thomsen, Reimar W and Lundby, Carina and Stidsen, Jacob Volmer and Højlund, Kurt and Ryg, Jesper and Reilev, Mette and Pottegård, Anton},
  title = {Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11086--11094},
  doi = {10.1111/dom.71308}
}
Kostenlos starten →